Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2021 Jul 16;12:706757. doi: 10.3389/fimmu.2021.706757

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright © 2021 Gilchuk, Guthals, Bonissone, Shaw, Ilinykh, Huang, Bombardi, Liang, Grinyo, Davidson, Chen, Gunn, Alter, Saphire, Doranz, Bukreyev, Zeitlin, Castellana and Crowe

This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

PMC Copyright notice

Therapeutic protection by class-representative plasma antibodies in mice. In vivo therapeutic protection by individual antibodies. C57BL/6 mice (n = 5 per group) were challenged with mouse-adapted EBOV-MA, treated at 1 day after virus inoculation with indicated antibody at a dose of 3.75 mg/kg, and monitored for 28 days. Dengue virus human antibody DENV 2D22 served as a control. Survival curves (top panel) were estimated using the Kaplan-Meier method, and each treatment group was compared to the DENV 2D22 group using a two-sided log-rank (Mantel–Cox) test. P-values are indicated for each comparison, and Bonferroni-corrected threshold for significance level was set up to P = 0.017. Weight change (middle panel) and illness score (bottom panel) are shown. Data represent one experiment.